- Home
- OVLY vs PLX Comparison
OVLY vs PLX Comparison
Compare OVLY & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVLY
- PLX
- Stock Information
- Founded
- OVLY 1990
- PLX 1993
- Country
- OVLY United States
- PLX United States
- Employees
- OVLY N/A
- PLX N/A
- Industry
- OVLY Major Banks
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OVLY Finance
- PLX Health Care
- Exchange
- OVLY Nasdaq
- PLX Nasdaq
- Market Cap
- OVLY 219.0M
- PLX 204.9M
- IPO Year
- OVLY N/A
- PLX 1998
- Fundamental
- Price
- OVLY $28.20
- PLX $1.91
- Analyst Decision
- OVLY
- PLX Strong Buy
- Analyst Count
- OVLY 0
- PLX 1
- Target Price
- OVLY N/A
- PLX $15.00
- AVG Volume (30 Days)
- OVLY 8.4K
- PLX 643.6K
- Earning Date
- OVLY 10-22-2025
- PLX 11-13-2025
- Dividend Yield
- OVLY 2.08%
- PLX N/A
- EPS Growth
- OVLY N/A
- PLX N/A
- EPS
- OVLY 2.84
- PLX 0.07
- Revenue
- OVLY $79,783,000.00
- PLX $61,840,000.00
- Revenue This Year
- OVLY N/A
- PLX $14.53
- Revenue Next Year
- OVLY N/A
- PLX $75.77
- P/E Ratio
- OVLY $10.13
- PLX $27.36
- Revenue Growth
- OVLY 2.98
- PLX 35.41
- 52 Week Low
- OVLY $22.70
- PLX $1.32
- 52 Week High
- OVLY $32.24
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- OVLY 53.18
- PLX 36.34
- Support Level
- OVLY $28.24
- PLX $1.70
- Resistance Level
- OVLY $30.05
- PLX $2.22
- Average True Range (ATR)
- OVLY 0.60
- PLX 0.14
- MACD
- OVLY 0.14
- PLX -0.06
- Stochastic Oscillator
- OVLY 48.32
- PLX 26.39
About OVLY Oak Valley Bancorp (CA)
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.